PMC:6019327 / 291248-291950 JSONTXT

{"project":"2_test","denotations":[{"id":"28506916-25753968-45814848","span":{"begin":147,"end":150},"obj":"25753968"},{"id":"28506916-25753968-45814848","span":{"begin":147,"end":150},"obj":"25753968"},{"id":"T62321","span":{"begin":147,"end":150},"obj":"25753968"},{"id":"T15966","span":{"begin":147,"end":150},"obj":"25753968"},{"id":"T1160","span":{"begin":147,"end":150},"obj":"25753968"},{"id":"T66157","span":{"begin":147,"end":150},"obj":"25753968"}],"text":"Another study assessed the feasibility for discontinuation of OAC after ablation based on the AF burden documented by implantable cardiac monitors.859 During a follow-up time of 32 ± 12 months (126 patient-years), 41 of the 65 patients (63%) had an AF burden \u003c1 hour per day and were able to stay off OAC. Twenty-one patients (32%) had to reinitiate OAC due to an AF burden \u003e1 hour, and three patients reinitiated OAC due to other reasons. No stroke, TIA, or other thromboembolic event was observed during follow-up. These are important data for those patients who decide not to receive chronic OAC, and we suggest consideration of an anticoagulation strategy based on AF burden measured by monitoring."}